Abstract 283P
Background
Prostate cancer is a type of cancer that occurs quite a lot in Indonesia, In 2020, prostate cancer ranks as the 11th most common cancer with 13,563 new cases (3.4%) and the 13th leading cause of death with 4,863 deaths (2.1%). Radiotherapy can be given in low, intermediate, high, and even metastatic states. However, The treatment of choice is influenced by several things, such as risk classification, performance status, patient choice, life expectancy, and access to radiotherapy services.The first step in providing access to radiotherapy services is to calculate the level of need for radiotherapy services.
Methods
The design of this study is cross-sectional, using secondary data on prostate cancer patients from cancer registration in 2019. Data collection starts in October 2022 and ends in January 2023. The 2019 data was chosen because it better describes the normal conditions during the pre-pandemic era. The collected data was identity, age, address, and data related to risk stratification and therapy. The optimal Radiotherapy Utilization Rate (oRUR) calculation method adopts the Collaboration for Cancer Outcomes Research and Evaluation (CCORE), which uses evidence-based guideline modeling methods.
Results
Using a decision tree (CCORE), the range of optimal RUR is 75.3% (66.7–78.3), and the actual RUR is 20.3%. The percentage of unmet need for prostate cancer at RSCM was 73.43% (69.5–74.07). In addition to radiotherapy, as many as 19 (14.3%) patients received chemotherapy treatment, 10 (8%) patients received surgical treatment, 42 (31.6%) patients received hormonal therapy, and 1 (0.8%) patient received samarium therapy.
Conclusions
This considerable difference between oRUR and aRUR can be caused by several things, such as a decrease in referrals to radiotherapy, inadequate and uneven access, fear and anxiety about radiation, adherence to National guidelines, and a limited number of radiotherapy service centers capable of providing radiation with the IMRT technique.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
485P - LDCT lung cancer screening of never-smokers meta-analysis subgroup analysis: Adenocarcinoma is the highly predictive histology identified in never-smokers
Presenter: Sai-Hong Ou
Session: Poster Display
Resources:
Abstract
486P - Fiscal feasibility and implications of integrating lung cancer screening into Hong Kong’s healthcare system
Presenter: Herbert Ho Fung Loong
Session: Poster Display
Resources:
Abstract
487P - Evaluating the performance of the USPSTF lung cancer screening guidelines in an Asian population of lung cancer patients
Presenter: Jian Wei Tan
Session: Poster Display
Resources:
Abstract
488P - Pulmonary ground glass opacity lesions: Immune ecosystem and its clinical relevances of early-stage lung adenocarcinoma
Presenter: Shensi Shen
Session: Poster Display
Resources:
Abstract
489TiP - BGB-LC-202 (NCT05577702): Phase II Umbrella study of tislelizumab (TIS) monotherapy and TIS-based immunotherapy combinations +/- chemotherapy (CT) as neoadjuvant treatment in Chinese patients (pts) with resectable stage II to IIIA non-small cell lung cancer (NSCLC)
Presenter: Wentao Yu
Session: Poster Display
Resources:
Abstract
491P - Furmonertinib as adjuvant therapy for elderly patients in resected EGFR-mutated non-small cell lung cancer: A double-center, real-world experience
Presenter: Ziheng Wu
Session: Poster Display
Resources:
Abstract
492P - Penpulimab-based combination neoadjuvant/adjuvant therapy for patients with resectable locally advanced non-small cell lung cancer: Preliminary results from a phase II study (ALTER-L043)
Presenter: Changli Wang
Session: Poster Display
Resources:
Abstract
493P - The prognostic value of 4L lymph node dissection in left-sided operable non-small cell lung cancer: A systematic review and meta-analysis
Presenter: Lei Peng
Session: Poster Display
Resources:
Abstract
495P - Intrinsic STING of CD8+T cells regulates self-metabolic reprogramming and exerts anti-tumor effects
Presenter: Qiuli Xu
Session: Poster Display
Resources:
Abstract
496P - Fruquintinib plus sintilimab in patients (pts) with advanced non-small cell lung cancer (NSCLC) with PD-L1-positive expression: A multicenter, single-arm phase II study
Presenter: Shun Lu
Session: Poster Display
Resources:
Abstract